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Background. Haitian immigrant women residing in Little Haiti, a large ethnic enclave in Miami-Dade County, experience the
highest cervical cancer incidence rates in South Florida. While this disparity primarily reﬂects lack of access to screening with
cervical cytology, the burden of human papillomavirus (HPV) which causes virtually all cases of cervical cancer worldwide, varies
by population and may contribute to excess rate of disease. Our study examined the prevalence of oncogenic and nononcogenic
HPV types and risk factors for HPV infection in Little Haiti. Methods. As part of an ongoing community-based participatory
research initiative, community health workers recruited study participants between 2007 and 2008, instructed women on self-
collecting cervicovaginal specimens, and collected sociodemographic and healthcare access data. Results. Of the 242 women who
contributed adequate specimens, the overall prevalence of HPV was 20.7%, with oncogenic HPV infections (13.2% of women)
outnumbering nononcogenic infections (7.4%). Age-speciﬁc prevalence of oncogenic HPV was highest in women 18–30 years
(38.9%) although the prevalence of oncogenic HPV does not appear to be elevated relative to the general U.S. population. The
high prevalence of oncogenic types in women over 60 years may indicate a substantial number of persistent infections at high risk
of progression to precancer.
1.Introduction
Haitian immigrant women residing in Little Haiti, a large
ethnic enclave in Miami-Dade County, experience the high-
est cervical cancer incidence rates in South Florida. Between
2007–2009, disease incidence in Little Haiti (34 per 100,000
women) was nearly four times higher than that reported for
the Miami metropolitan area overall (9 per 100,000 women)
[1]. This disparity reﬂects lack of access to the formal health-
care system and screening with cervical cytology (Papanic-
olaou test) [2, 3]. While cytology-based screening programs
have eﬀectively reduced cervical cancer incidence and mor-
tality in the United States [4, 5], Haitian women in Little
Haiti encounter multiple barriers to routine Pap testing, and
often cannot comply with screening recommendations or
necessary follow up for detected abnormalities [6, 7].
Underutilization of screening may not solely account for
the excess burden of cervical cancer observed among Haitian
women. Epidemiologic and virologic studies have shown
that persistent cervical infection with oncogenic “high risk”
human papillomavirus (HPV) types cause virtually all cases
of cervical cancer worldwide [8], but the prevalence of HPV2 Journal of Oncology
varies by population. Knowledge of the burden of HPV by
type and age will be necessary to establish the utility of
vaccines against HPV infection and for the eﬀective design
of screening protocols with HPV DNA testing, which may
improve uptake of screening in populations with access bar-
riers if self-sampling of HPV DNA specimens proves accept-
able and feasible. Using a community-based participatory
research (CBPR) approach, our primary objective was to do-
cument the prevalence and type distribution of HPV in Lit-
tleHaiti,whichtodatehasnotbeendescribed.Wealsoexam-
ined risk factors associated with oncogenic HPV infection in
our sample.
2. Methods
2.1. Overview of Patn` e en Aksyon. The current study was
conducted as part of an ongoing CBPR initiative in Little
Haiti, which has been described in previous publications
[2, 3, 9]. Brieﬂy, CBPR is a research methodology, increas-
ingly popular in the ﬁeld of public health, which invites
community participation throughout the research process,
from study conceptualization to dissemination of ﬁndings
[10–12]. This approach helps dissuade community suspicion
about the intent of inquiry, which is prevalent in Little
Haiti and other underserved communities that are largely
disenfranchised from the formal healthcare system.
In Little Haiti, CBPR eﬀorts are governed by a campus-
community partnership known as Patn` e en Aksyon (Part-
ners in Action). This partnership, which involves active
participation of community leaders from Little Haiti and an
interdisciplinary team of investigators from a large university
in the Miami metropolitan area, strives to reduce the excess
burdenofcervicalcancerexperiencedbyHaitianwomenand
to improve the health status of women in Little Haiti. To this
end, community health workers (CHWs), who are formally
employed by a large community-based organization whose
leadership is active in Patn` e en Aksyon, play a central role.
2.2. Participant Recruitment and Data Collection. In the
present study, female CHWs of Haitian descent (ﬂuent in
English and Haitian Kreyol) were trained to recruit study
participants and collect data using a standardized manual
created by one of the academic partners. As part of the
training, each CHW also completed an online certiﬁcation
program for conducting human subjects research (CITI), as
mandated by the University of Miami’s Institutional Review
Board (IRB). The university IRB approved the study.
Between September 2007 and March 2008, CHWs re-
cruited participants primarily through the extensive network
of the community-based organization (CBO) where they
were formally employed, and by canvassing community ven-
ues including ﬂea markets, health clinics, and laundromats
acrossLittleHaititoidentifywomenmeetingstudyeligibility
criteria (i.e., were 18 years of age and older, had no prior
history of cervical cancer or surgical hysterectomy, and re-
ported having no Pap smear within the past year). The
CHWs approached all women in such venues who appeared
to be of Haitian descent and at least 18 years of age (n=362)
and told them about the study. For women who were
interested and eligible (n = 290), the CHWs scheduled an
interview to have women self-sample for HPV and respond
to a short survey.
Interviews and self-sampling took place wherever the
participant felt most comfortable, usually at her home or the
home of a close friend, and were conducted in English or
Haitian Kreyol according to the participant’s preference. The
CHWs were instructed to (1) obtain informed consent, (2)
teach women how to appropriately self-sample using visual
aids, and (3) interview participants about their experience
with self-sampling. To monitor adherence to this research
protocol,CHWswererequiredtologthetimethattheycom-
pleted each step on data collection forms. Given widespread
skepticism about research in Little Haiti, the CHWs spent
one hour (on average) explaining to participants the beneﬁts
of participation, explaining the purpose of collecting spec-
imens and genotyping those positive for HPV, and assuring
women that results would be kept conﬁdential. Following
informed consent, CHWs instructed women on how to
appropriately use the device using a pictorial brochure that
visually demonstrated each step in the process (Figure 1).
The participants then collected their sample in private and
gave it to the CHW. Immediately afterwards, the CHW ad-
ministered abriefquestionnaire, whichassessedparticipant’s
impressions about self-sampling for HPV sociodemographic
background, Pap smear screening history, and risk factors
for HPV. Questionnaire items were adapted from previously
validated women’s health behavior surveys and were trans-
lated and back-translated from English to Haitian Kreyol for
monolingual Kreyol participants.
The CHWs notiﬁed all participants of their results, and
assisted those with cytological abnormalities and/or infec-
tions (e.g., candida, gardnerella, trichomoniasis) in obtain-
ing timely and appropriate followup care. Nearly all women
with abnormalities obtained follow-up at a free gynecologic
oncology clinic in Little Haiti with the assistance of CHWs.
2.3. Specimen Collection. Women self-collected cervicovagi-
nal specimens with the Fournier device, which has demon-
strated high concordance with physician-collected cervical
specimens and can provide specimens for cytology assays
[13, 14]. This device is currently only approved for research
purposes, but is under review by the FDA for clinical appli-
cation.Mechanicallysimilartoatampon,thedeviceincludes
anoutersheathtopreventcross-collectionofunwantedvagi-
nal cells that may compromise specimen quality and reliabi-
lity. Women were instructed to insert the device into their
vagina, eject the Dacron tip to obtain a sample of cervical
cells for cytology, and then retract the tip to avoid cross-
collection of vaginal cells during removal (Figure 1). Speci-
mens were shipped to Select Diagnostics (Greensboro, North
Carolina) for HPV testing, genotyping, and cytological eval-
uation. Cytology was performed using standard Thin Prep
technology [15].
2.4. Human Papillomavirus Detection and Typing. Cervicov-
aginal specimens were genotyped using a polymerase chainJournal of Oncology 3
This is the Fournier self-
sampler. It is just like the 
Pap test given to you by a 
doctor, but you do it 
yourself. The self-sampler 
tests for infections and 
abnormalities in a 
woman’s cervix. 
During pregnancy, 
the baby grows inside 
a woman’s uterus. The 
bottom part of the 
uterus is called the 
cervix. The cervix can 
be felt high inside the 
vagina. The cervix is 
where cervical cancer 
can develop. 
The Fournier self-sampler can help prevent 
cervical cancer. Regular use of the sampler can 
detect infections and other abnormalities in 
the cervix that may lead to cancer if left un-
treated. The Fournier sampler is easy to use. 
You can use it at any time of day in any place 
you feel comfortable. Just follow these simple 
steps: 
(1) First wash your hands with soap and warm water. 
(2) After you wash your hands, undress from the 
waist down. Please remove all of your clothing 
including your underwear. 
(3) Next take the sampler 
out of the package. It is 
ready to use. All you have 
to do is put the sampler 
into your vagina. Push the 
sampler in as far as it can 
go. If you use tampons 
during your menstrual 
period, using the sampler 
is similar to using a     
tampon.
(4) Once you have 
inserted the sampler, 
push up the bottom, 
which looks like a 
ﬂower, to release the 
tip. The tip is what 
collects cervical cells 
for testing. 
(5) Now, move the     
entire sampler up and 
down ﬁve times, making 
sure not to pull it out 
completely. With the 
sampler all the way in, 
turn the bottom part of 
the sampler, which 
looks like a ﬂower, 
around ﬁve complete 
times. 
(6) You have ﬁnished 
using the sampler! 
Before removing it 
from your vagina, pull 
the bottom part of the 
sampler, which looks 
like a ﬂower, down so 
that the tip goes back   
inside. 
(7) Once you have 
removed the sampler 
from your vagina, get 
dressed, and hand 
the device to the 
community health 
worker. She will put 
the tip in a special 
jar. 
You are done! Someone will contact you with 
concerns before then, please contact the Haitian 
American Association Against Cancer (HAAAC). 
your results in 3-4 weeks. If you have questions or
Uterus
Cervix
Vagina
Figure 1: Self-sampling device brochure.
reaction restriction fragment length polymorphism (PCR-
RFLP) assay (Access Genetics, Eden Prairie, MN), which
ampliﬁes the highly conserved L1 region of the HPV genome
to detect approximately 80 HPV types. Genomic DNA was
extracted from ecto- or endocervical epithelial cells ob-
tained via the Fournier device and ﬁxed in alcohol-based liq-
uidThinPrep™ (CytycInc,Boxborough, MA)solution using
standard techniques. In brief, cellular material was con-
centrated and the alcohol preservatives removed by distilled
water dilution. Each sample was evaluated for cellularity to
determine the dilution volume that equalizes the concen-
trations across all samples followed by an enzymatic incu-
bation to achieve increased cell membrane permeability. An
aliquot of each cellular sample was then combined with Cel-
lerate Access Genetics, Eden Prairie, MN. This mixture was
subjected to thermal cycling incubation resulting in protein
degradation and the release of puriﬁed DNA.
PCR ampliﬁcation of HPV products used degenerate
primers speciﬁc for the consensus regions of the L1 gene in
the HPV genome. The assay was performed in two parts:
HPV detection (presence/absence) and HPV identiﬁcation
(RFLP genotyping). The ﬁrst reaction included two unique
and speciﬁc primers, one for the HPV genome, and the other
for the β-globin housekeeping gene. The latter was used
as an internal control to document the presence of human
nucleated cells in the sample analyzed. PCR products were
then simultaneously separated and stained for visualization
using 3% agarose gels prestained with ethidium bromide.
Electrophoresiswasperformedin1XTBEbuﬀerat ∼95Vfor
90 minutes. Images of each gel were digitally captured. HPV
type was determined by RFLP. A PCR product from each
HPV-positive sample underwent endonuclease digestion
with restriction enzymes Pst I, Rsa I, and Hae III. The diges-
tion products were separated using 5% polyacrylamide gel
electrophoresis (PAGE). The resultant fragment band pat-
ternsdeterminedthespeciﬁcHPVtypespresentineachsam-
ple.
For this analysis, oncogenic “high-risk” (HR) HPV types
included 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 68, 73, and 82 [16, 17]. All other HPV types, including
unknown types, were considered low risk (LR).
2.5. Statistical Analyses. Among the 290 women eligible for
the study, 246 completed self-sampling and the subsequent4 Journal of Oncology
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Figure 2:Age-speciﬁcprevalenceofcervicalhumanpapillomavirus(HPV)DNAbyLR,HR,andHRTypes16and18. Vertical bars indicated
95% conﬁdence intervals of overall HPV prevalence. (Black) HPV 16 and/or 18 (including co-infection), (grey) all other HR-HPV, (white)
LR-HPV only.
questionnaire. Of these, we included 242 women in the pre-
sent analysis; the four excluded women did not collect ade-
quate specimens for HPV testing. All data were managed and
analyzed in SAS version 9.2 for Windows (SAS Institute Inc.,
Cary, NC, USA). Frequency distributions of HPV infection
andHPVtypeswerecalculatedfortheentiresampleandthen
stratiﬁed according cytology result (normal versus abnor-
mal [ASC-US+]). We also estimated HPV prevalence by age
group (18–30; 31–40; 41–50; 51–60; >60 years) according to
risk class (HPV 16/18, other HR, and LR types). To deter-
minefactorsassociatedwithprevalentHRHPVinfection,we
calculated odds ratios (ORs) and 95% conﬁdence intervals
with unconditional logistic regression models (univariate
and adjusted for age). The reference group consisted of
women with LR or no HPV. Women with multiple infections
were included in the HR HPV group if at least one infection
was with a HR HPV type.
3. Results
The vast majority of women (85.1%) were over 30 years of
age(Table 1).Mostparticipants(97.1%)werenotborninthe
United States, but 74% had been in the USA for more than
5 years. While 49.6% reported a regular place for receiving
healthcare, only 14.9% had health insurance. A signiﬁcant
proportion of women (79.3%) reported having had a Pap
smear in their lifetime and 60.3% had been screened within
the past 3 years. Approximately half (52.5%) of the sample
were married or cohabitating, were employed part or full-
time (55.8%), and reported more than 3 pregnancies in their
lifetime (49.6%). Inﬂammation was present in cytological
specimensfor45.9%ofwomen,andtheprevalenceofvaginal
infections with candida, gardnerella, or trichomoniasis was
33.1% (data not shown).
Table 2 reports the overall rates of HPV infection and
prevalence by type among participants. Of the 50 women
infected with HPV (20.7%), 8 were infected with multiple
HPV types (3.3% of all women, 16% of HPV-positive
women). HR HPV infections (13.2%) were considerably
more common than LR infections (7.4%) among all women.
The most prevalent HPV types, detected as either single or
multiple infections, were HPV 53, 82, and 61 (each detected
i n5w o m e n ) .H P V1 6o r1 8w e r ed e t e c t e di n5s p e c i m e n s .
Two samples were HPV positive but could not be genotyped
and were subsequently classiﬁed as LR.
Overall, 21 women (8.7%) had abnormal cytology re-
sults, including 14 with atypical cells of undetermined signi-
ﬁcance (ASC-US), 1 with atypical glandular cells not other-
wise speciﬁed (AGC-NOS), 4 with low-grade intraepithelial
lesions (LSIL), and 2 with high-grade intraepithelial lesions
(Table 3). Of women with abnormal cytology results, 16/21
(76.1%) had detectable HPV; of women with normal cytol-
ogy results, 34/221 were HPV-positive (15.3%). The most
common HPV types among women with abnormal cytology
w e r eH P V8 2 ,3 5 ,a n d6 1( e a c hf o u n di n2w o m e n ) .T h et w o
women with HSIL were infected with HPV 35 and 82. There
was no association between cytology result and risk class of
HPV (P = 0.88).
Figure 2 shows the prevalence of HPV (by HPV 16 or
18, other HR HPV, and LR types) across age strata. The age-
speciﬁc prevalence of HPV decreased from 44.5% (95% CI:
29.360.7%) in those aged 18–30 to 15.2% (95% CI: 8.4–
25.9%) among women 31–40, 16.4% (95% CI: 9.9–25.6%)
in women 41–50, and 12.9% (95% CI: 4.9–29.7%) in 51–
60 year olds. Prevalence increased to 26.1% (95% CI: 12.2–
47.2%) among women aged 61 years and over. Similarly, the
prevalence of HR HPV infections was highest in 18–30 year
olds(38.9%),fallingto9.1%,8.2%,and3.2%inwomenaged
31–40 years, 41–50 years, and 51–60 years, respectively, andJournal of Oncology 5
Table 1: Characteristics of 242 cervical self-sampling participants.
N %
Age 18–30 36 14.9
31–40 66 27.3
41–50 86 35.5
51–60 31 12.8
>60 22 9.1
Education < High school 119 49.2
High school 49 20.3
> High school 74 30.6
Years in USA <5 63 26.0
6–10 82 33.9
>10 97 40.1
Marital Status Never been married 71 29.3
Married/living with partner 127 52.5
Divorced/widowed/separated 44 18.2
Employed 134 55.8
Unemployed 95 39.6
Homemaker/Student/Other 11 4.6
Income <15K 121 50.0
Have health insurance 36 14.9
Have a regular place for healthcare 120 49.6
Read/Speak Creole Only 98 40.7
Mean SD
Number of pregnancies 3.8 2.6
Age at ﬁrst pregnancy 22.9 5.1
then increasing to 17.4% among women 61 years and over.
By contrast, the prevalence of LR infections was lowest in
18– 30 year olds (5.6%) and highest in older women (9.7%
in 51–60 year olds). HPV 16 and 18 were found exclusively
among women between 18 and 40 years, with 5 out of
6 infections occurring in women aged 30 and under. HR
HPV infections outnumbered LR infections in the youngest
and oldest age groups, while LR infections were at least as
prevalent as HR infections in women between 41 and 60
years.
Table 4 shows the crude and age-adjusted ORs from lo-
gisticregressionmodelsforprevalentinfectionwithHRHPV
and the major characteristics of women in the study. In uni-
variate analyses, younger age, never being married, being
born outside the USA, never having been pregnant, and ever
being exposed to tobacco were signiﬁcantly associated with
HR HPV infection. However, when we adjusted for age
group, only ever exposure to tobacco smoke at home re-
mained signiﬁcantly associated with HR HPV infection (OR
= 4.05, 95% CI: 1.2–12.8; P<. 01). There was a low
prevalence of concomitant sexually transmitted infections
(STIs) in our sample including 13 cases of Chlamydia and
1 case of Gonorrhea. There was no signiﬁcant association
between STI infection and any HPV infection, HR HPV
infection, or abnormal cytology. There were no signiﬁcant
associations between HR HPV positivity and vaginal infec-
tion.
4. Discussion
These data are the ﬁrst to estimate the prevalence of HPV
and distribution of infections by type and age in Haitian
immigrants living in the USA. The crude prevalence of any
HPV (20.7%) and HR HPV (13.2%) in this sample was
slightly lower than estimates from a representative sample of
USA women aged 15–49 years who provided self-collected
HPV specimens (any HPV: 26.8%; HR HPV: 15.2%) [18].
Our estimates of any or HR HPV prevalence, both overall
and for ages 60 and under, tended to be slightly lower
than those reported by other USA-based studies [19–22].
Diﬀerences in study populations, statistical uncertainty, and
HPV sampling and detection methods likely account for
subtle diﬀerences.
We found that HR HPV types 53, 82, 52, and 68 and
LR HPV types 61 and 62 were the most prevalent in
the study population. This type distribution contrasts with
ﬁndings from a meta-analysis of other USA-based studies,
which found HPV 16, 52, 18, 51, and 58 to be the most
prevalent types among women with normal cytology [23].
While the prevalence of HPV 16 tends to increase with
the degree of cytologic abnormality (both in the USA and
worldwide) [24], we found a relatively low prevalence of
HPV 16 (1.2%), and none of these infections were asso-
ciated with abnormal cytology. Cancer registry data aggre-
gates individuals by broad race-based classiﬁcations and6 Journal of Oncology
Table 2: Cytology results and type-speciﬁc HPV prevalence among
242 residents of Little Haiti.
Cytology results Normal Abnormal∗
n (% of row total)
Total 221 (91.3%) 21 (8.7 %)
HPV − 187 (97.4%) 5 (2.6%)
HPV + 34 (68%) 16 (32%)
HR HPV + 22 (69%) 10 (31%)
LR HPV +/ Unknown 12 (67%) 6 (33%)
HR infections Type No. of infected women
53 4 0
82 1 2
52 3 0
68 2 1
16 2 0
35 1 2
18 1 1
33 2 0
45 2 0
66 0 1
31 0 1
LR infections
61 2 2
62 0 0
83 2 1
CP108 1 0
11 1 1
72 1 0
84 1 0
Unknown 2 0
42 0 1
44 0 1
Multiple HR infections 4 2
16 & 84 1 0
52 & 53 0 1
62 & 66 1 0
62 & 68 1 0
82 & CP108 1 1
Multiple LR infections 2 0
62 & 61 1 0
62 & 72 1 0
∗Abnormal cytology includes the following diagnoses: ASC-US (n = 14),
AGS-NOS (n = 1), LSIL (n = 4), and HSIL (CIS, CIN2, and moderate
dysplasia, n = 2).
ethnicity data is often lacking and incomplete. Therefore,
the HPV type distribution among cervical cancer cases in
the Haitian immigrant population of Miami is unknown.
The distribution of HPV types among women in Little Haiti
bares similarity to study results from Dunne and colleagues
[18], which also found HPV 53 to be the most prevalent
HR HPV type in a representative USA sample, followed by
HPV 52; HPV 62 was the most prevalent LR type. While
we used a diﬀerent self-sampling device than Dunne et al.
Table 3: Distribution of HR HPV types and cytology results.
Total HR HPV positive
women 32 (13.2%)
Type No. of infected
women n (%)
Abnormal
(n = 10)
Normal
(n = 22)
16 2 (5.2) 0 2
18 2 (5.2) 1 1
31 1 (2.6) 1 0
33 2 (5.2) 0 2
35 3 (7.9) 2 1
45 2 (5.2) 0 2
52 3 (7.9) 0 3
53 4 (10.5) 0 4
66 1 (2.6) 1 0
68 3 (7.9) 1 2
82 3 (7.9) 2 1
HR coinfections∗ 6 (15.8) 2 4
n/total (%)
Diﬀerential cytology results ASC-US 6 6/14 (42.8)
among HR-HPV positive LSIL 1 1/4 (25)
women HSIL 1 1/2 (50)
HPV: human papillomavirus, HR: high risk (oncogenic HPV type).
∗Coinfections by types 16 & 84, 52 & 53, 62 & 66, 62 & 68, (n = 1f o re a c h
listed) and CP6108 & 82 (n = 2).
and the Fournier device used in our study was designed to
improve collection of cervical cells while minimizing sam-
pling from the vagina, it is possible that the similar respective
type distributions are an artifact of self-sampling. However,
a study of paired vaginal and cervical specimens did not
ﬁnd signiﬁcant diﬀerences in prevalence of HR HPV types
(including the most prevalent ones in our study) based
on sampling location; diﬀerences in HPV type distribution
between cervical and vaginal specimens are more likely to
arise among LR types in phylogenetic groups α3( w h i c h
includes HPV 61 and 62) and α15 [25]. Thus, the relatively
high prevalence of HR HPV 53, 82, and 68 among our study
population relative to meta-analysis of other USA studies
would not appear to be a function of inadvertent sampling
of vaginal cells.
DataonthetypedistributionofHPVinHaitiiscurrently
unavailable [26], although we are collecting in-country data
that will allow for estimation of HPV burden and compa-
rison between Haitian immigrants in the U.S. and women
living in Haiti. Elsewhere in the Caribbean, overall HPV pre-
valence is higher than in our study. HPV 45 appears to be
the most common HR type in Jamaica and Tobago [27, 28],
whileHPV52isthemostprevalentHRtypeinTrinidad[29].
Geographical diﬀerences in the relative prevalence of HPV
types—among Caribbean countries and the United States—
may be inﬂuenced by an interaction between HPV types and
host immunogenetic proﬁle (for instance, human leukocyte
antigen [HLA] polymorphisms) [24, 30]. HPV 16, the most
oncogenic HPV type, appears to evade immune surveillance
moreeﬀectivelythanothertypes[31].ImpairmentofcellularJournal of Oncology 7
Table 4: Crude and age-adjusted odds ratio estimates of HR HPV infection to negative and LR HPV infection (n = 242).
Age % Crude OR
(95% CI) P value Age-adjusted
∗OR (95% CI) P value
18–30 14.9 1
31–40 27.3 0.16 (0.05–0.51) — —
41–50 35.5 0.14 (0.04–0.43) — —
51–60 12.8 0.05 (0.01–0.41) — —
>60 9.1 0.34 (0.07–1.32) <.001 — —
Educational
attainment
< High school graduate 49.2 1 1
=> High school graduate 50.8 1.5 (0.70–3.17) 0.3 1.04 (0.38–2.88) 1
Marital status
Never married 29.3 1 1
Married/cohabitating 52.5 0.39 (0.18–0.86) 0.63 (0.24–1.65)
Divorced/Widowed/Separated 18.2 0.07 (0.01–0.58) <.01 0.15 (0.01–1.15) 0.12
Place of birth
US born 2.9 1 1
Born abroad 97.1 5.33 (1.14–25.0) <.001 1.22 (0.15–8.8) 1
Years in the United
States
<5 years 26.0 1 1
5–10 yrs 33.9 0.73 (0.30–1.82) 1.02 (0.35–3.07)
>10 years 40.1 0.54 (0.22–1.37) 0.43 1.05 (0.33–3.36) 1
Employment status
(n = 240)
Unemployed 39.6 1 1
Employed part or full time 55.8 1.19 (0.53–2.64) 1.27 (0.50–3.35)
Homemaker/Student/Other 4.6 2.86 (0.66–12.4) 0.37 1.19 (0.16–7.01) 0.90
Menopause status
Premenopausal 68.6 1 1
Postmenopausal 31.4 2.17 (0.85–5.51) 0.08 2.68 (0.47–29.8) 0.31
Number of
pregnancies
None 9.5 1 1
1–3 40.9 0.24 (0.09–0.65) 0.34 (0.1–1.19)
>3 49.6 0.14 (0.05–0.41) <.01 0.29 (0.07–1.26) 0.10
Age at ﬁrst pregnancy
(n = 215)
Under 18 12.1 1 1
18–25 51.6 1.88 (0.40–8.76) 2.67 (0.51–27.5)
26–41 36.3 1.0 (0.19–5.3) 0.38 1.61 (0.24–19) 0.33
Ever tobacco use
Nonsmoker 86.8 1 1
Former or current smoker 13.2 0.93 (0.30–2.85) 0.90 0.71 (0.16–2.5) 0.78
Ever exposed to
tobacco smoke at
home
Nonexposed 1 1
Exposed 10.3 3.11 (1.18–8.21) 0.03 4.05 (1.2–12.8) <.018 Journal of Oncology
Table 4: Continued.
Age % Crude OR
(95% CI) P value Age-adjusted
∗OR (95% CI) P value
Health insurance
(n = 241)
None 85.1 1 1
Yes 14.9 1.07 (0.38–3.0) 0.90 0.76 (0.20–2.43) 0.79
Regular place for
healthcare
None 50.4 1 1
Yes 49.6 1.02 (0.48–2.15) 0.96 1.06 (0.44–2.56) 1
Inﬂammation
Absent 54.1 1
Present 45.9 0.78 (0.37–1.67) 0.52 0.96 (0.38–2.41) 1
Any STI∗∗
Absent 94.6 1 1
Present 5.4 1.21 (0.26–5.7) 0.82 0.68 (0.12–3.69) 0.72
Vaginal infection‡
T. Vaginalis 9.5 0.98 (0.28–3.52) 0.98 0.87 (0.14–3.74) 1
Gardnerella 20.2 1.66 (0.72–3.87) 0.24 1.40 (0.50–3.65) 0.6
Candida spp. 7.4 0.81 (0.18–3.69) 0.78 0.77 (0.08–4.1) 1
Multiple Vag. Infection 4.1 0.72 (0.09–5.9) 0.72 0.89 (0.2–7.9) 1
Any Vag. Infection 33.1 1.46 (0.68–3.13) 0.33 1.18 (0.47–2.85) 0.84
Likelihood ratio test P-value; bolded values indicate a signiﬁcant diﬀerence comparing response to reference level at P < 0.05.
∗OR (95% CI): Age-adjusted Odds ratio and 95% conﬁdence interval; reported P-value from exact method and Score test.
∗∗Includes HIV/AIDS (n = 0), Gonorrhea (n = 1), and Chlamydia (n = 13).
‡Same woman can be counted more than once due to multiple infections; OR is odds HR HPV infection for women with speciﬁc vaginal infection compared
to those without.
immunity in a population (through immunocompromise or
cervicalinﬂammation,forinstance)couldthusleadtohigher
relative prevalence of HR types other than HPV 16 [24].
Haitian women routinely practice feminine hygiene with a
wide-variety of solutions containing natural and commercial
products. The very high frequency of cleansing, 2-3 times
dailyformostwomen,maybecausinginﬂammationanddis-
rupting the immune function of cervical cells. We note that
the high level of cervical inﬂammation in our study (45.9%)
may contribute to the high prevalence of non-16 HR types.
Age patterns associated with HPV prevalence vary by
population. The prevalence of HPV among Haitian women
living in Miami was highest in young women (44.5%),
decreasing with age until rising to a second minor peak in
women over 60 years (26.1%). A recent meta-analysis sug-
gests that HPV prevalence in the USA declines steadily with
age [23]. Data from Latin America and Central America, on
the other hand, indicate a U-shaped curve, with prevalence
declining through middle age but increasing again in older
women [32–34]. The high prevalence of HR HPV among
women over 60 years in our study population (17.4%) is
cause for concern, particularly in light of low screening
uptake. Prevalently detected infections in older women tend
to represent persistent infections with an elevated risk of
progression to cervical intraepithelial neoplasia grade 2 and
higher (CIN2+) [35]. Our ﬁndings highlight the importance
of improving screening coverage among older women in Lit-
tle Haiti.
Wefoundslightlyelevatedlevelsofcytologicalabnormal-
ities (8.7%) compared to approximately 6% in the general
USA population [36]. Still, few studies have examined the
validity of cytological results obtained from samples self-
collected with the Fournier device [13], so we interpret this
ﬁnding with caution.
There are several limitations to this study. Our original
study’splannedsamplesize(300)wascalculatedbasedonthe
95% exact conﬁdence interval approach and good precision
(i.e., less than 6%). In our study the observed prevalence
of HPV for 242 evaluable women is 20.7% with 95% exact
conﬁdence interval of 15.7% and 26.3%. Therefore, our
study established with high conﬁdence (97.5%) that the true
HPV prevalence in the target population is not less than
15.7%. Our study size is suﬃciently large to ensure good
precision, that is, a 5.3% semiwidth conﬁdence interval,
for estimating the HPV prevalence in this population. The
sample size was reduced as a result of budgetary restraints
and input from key members of the community advisory
board. As a part of an ongoing CBPR initiative, it was ne-
cessary to balance the achievement of recruitment goals
againstthe logistical constraints imposed by utilizing CHWs,
who held roles in both this research study and as employees
of various other community-based organizations.Journal of Oncology 9
Our sample size was small and when we stratiﬁed by age
group we lost power to detect signiﬁcant predictors of HR
HPV infection. While age and exposure to tobacco smoke at
home were signiﬁcantly associated with HR HPV infection
among our sample, the signiﬁcance of other predictors was
diﬃcult to discern after adjusting for age. Furthermore, this
was not a population-based sample, and results may not
be fully generalizable to women living in Little Haiti. Near-
ly 80% of participants in this study reported receiving a Pap
smear in the past three years, which is considerably high-
er than the 44% indicated by our previous work with women
in Little Haiti [3]. We attribute the higher utilization of
screening in the current study population to the community
partners’ unwillingness to limit inclusion to women who had
never been screened in their lifetime. Participant selection
may be a limitation of the study; CBPR relies upon commu-
nity participation to deﬁne the focus of research and identify
culturally appropriate recruitment strategies and methods
of data collection. Our partnership with the community-
based organization, and the aﬃliated CHWs, was critical to
the high participation rate achieved. We encountered few
barriers to study implementation and were able to build
organizational capacity to support future research and inter-
vention. Importantly, we were also able to ensure that data
could be generated by the community and for the communi-
ty’s beneﬁt.
Due to cultural considerations raised by our partner
community-based organization, we could only collect data
onbroadagegroups,andwerelimitedinourabilitytocollect
data on sexual behavior. Both age and sexual behavior are
demonstrated predictors of HPV infection, and our inability
to adjust for these in multivariate analysis is a limitation. We
also rely on validity assessments of the self-sampling method
from other studies, as we were not able to compare self-
collected specimens to physician-collected specimens here.
We cannot rule out the possibility that women may not have
self-sampled correctly.
This cross-sectional study is a preliminary investigation
into the prevalence and distribution of HPV types among
women in Little Haiti, Miami, Florida. Among participants,
the burden of vaccine types 6, 11, 16, and 18 was low, but
further study will be needed to determine the prevalence of
HPV 16 and 18 in Haitian immigrants with cervical can-
cer. Although the prevalence of HPV and HR HPV does not
appear to be elevated among women in Little Haiti relative
to the general USA population, we note the unusually high
prevalence of HR HPV among women over 60 years, which
may indicate a substantial number of persistent infections
at high risk of progression to CIN2+. Underutilization of
screening is undoubtedly a contributing factor to the high
incidence of cervical cancer, but further study is needed to
explain the excess cervical cancer burden in this population
relative to others in South Florida. We are presently exam-
ining common feminine hygiene practices in this commu-
nity of Haitian immigrants that may physiologically alter
the cervix. Changes induced by exposure to particular com-
pounds may reduce a woman’s ability to clear infections,
placing women at a greater risk of persistent HR HPV in-
fection.
Self-collectionofHPVspecimenshasbeendemonstrated
to be acceptable and feasible among women in Little Haiti
[2], and the present study points to the need to address
screening disparities in this population, particularly among
older women. We hope that the ﬁndings we present here
catalyze further research and the movement of resources
toward implementation and scale up of screening programs
tailored to underserved populations in the United States.
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